Developer docs
API playgroundTry for free, no card

Search company profiles

Biotricity

Full company profile

uuid0003v7s

Namestring
Biotricity
Legal namestring
Biotricity Inc.
Websiteurl
biotricity.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Biotricity Inc. (NASDAQ: BTCY) is a medical technology company headquartered in Redwood City, California, that develops FDA-cleared remote cardiac monitoring hardware and an integrated cloud-based disease management platform. Founded in 2014–2015 by Dr. Waqaas Al-Siddiq and listed on Nasdaq in 2021, the company targets two distinct end markets: clinical cardiology (via physician-prescribed devices reimbursable under RPM and Holter CPT codes) and consumer health (via direct-to-consumer e-commerce). Its core product portfolio spans Bioflux (cellular cardiac outpatient telemetry), Biocore and Biocore Pro (3-lead wireless cardiac monitors — the latter with a built-in SIM card), Bioheart (personal 24/7 heart rhythm monitoring), Biokit (multi-vital RPM kit with blood pressure cuff, pulse oximeter, and thermometer), and the Biocare software platform that unifies diagnostics, remote patient monitoring, telemedicine, and chronic care management.

The Biocare platform functions as the technical backbone across the portfolio: continuous ECG streams from Biotricity devices are analyzed using AI-driven anomaly detection, transmitted automatically via cellular or Bluetooth, and surfaced to physicians through a diagnostic portal with automated reporting and threshold-based alerts. The Biocore Pro is described as the only 3-channel cardiac monitor with integrated cellular data transfer, and devices such as Biocore support up to 30 days of recording with daily recharging. Hardware is supported by 15 issued patents and 14 pending applications covering 3-lead ECG architectures, cellular connectivity, and a versatile multi-sensor patch/watch form factor.

Biotricity generates revenue from four streams: hardware/device sales (Bioflux, Biocore, Biocore Pro, Bioheart, Biokit), recurring subscription revenue from the Biocare platform, insurance-reimbursable RPM services billed by clinics, and one-time consumer service fees (notably the HeartSecure 10-day program at $149–$199). The company distributes through physician/clinic direct sales (over 2,500 healthcare professionals using Biocore), the Biodirect direct-to-patient shipping program, healthcare provider networks, and its own e-commerce storefronts. As of Q3 FY2026, quarterly revenue was $3.99 million, with 9-month FY2025 revenue of $11.7 million (up 16% year-over-year); however, the company carries an accumulated deficit of $142.1 million and a working capital deficiency of $18.8 million, signaling that growth has not yet translated to profitability.

Short descriptiontext

Biotricity is a Nasdaq-listed medical technology company that develops FDA-cleared remote cardiac monitoring devices — including Bioflux, Biocore Pro, Bioheart, and Biokit — and the Biocare cloud platform for cardiac diagnostics, remote patient monitoring, and chronic care management serving physicians, cardiology clinics, and consumers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
remote cardiac monitoring, medical monitoring devices, heart rhythm monitoring, remote patient monitoring, cardiac diagnostics platform
Industry5 codes
PRIMARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYCRACAQAC
ECG/EKG & Heart Rhythm Monitors (Consumer)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Remote cardiac monitoring devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Device/Hardware Sales
TypeHardware Sales
Description

Sale of FDA-cleared cardiac monitoring devices including Biocore, Biocore Pro, Bioheart, and Biokit to healthcare providers and consumers.

biospace.com
2Subscription/Recurring Revenue
TypeSubscription Recurring
Description

Recurring revenue from subscription services including cloud data storage, diagnostic analysis, and platform access fees for healthcare providers using Biocare.

sec.gov
3Insurance Reimbursement
TypeManaged Services
Description

Healthcare providers can bill insurance for remote patient monitoring services using Biotricity devices. Biocore Pro enables physician-enabled billing where clinic revenue from claims is paid directly to the clinic, not the device vendor.

biotricity.com
4HeartSecure Program
TypeOne Time License
Description

One-time cardiac monitoring service at $149-$199 for 10-day comprehensive heart analysis including device rental, cardiologist review, and detailed report delivery.

biotricity.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Pricing details3 tiers
1HeartSecure - 10-Day At-Home Cardiac Monitoring
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$149-$199 for comprehensive 10-day heart analysis including device, prepaid shipping, expert cardiologist review, and detailed heart health report with no hidden fees.

biotricity.com
2Biocore/Biocore Pro - Physician Prescribed
ModelOtherBilling cadenceMulti-year contract
Notes

Prescription-based cardiac monitoring device. Pricing determined through healthcare provider/clinic billing. Insurance reimbursable under CPT codes for remote patient monitoring and Holter monitoring.

biotricity.com
3Bioheart - Consumer Direct
ModelSubscriptionBilling cadenceMonthly
Notes

Consumer wearable for continuous heart monitoring. Sold through e-commerce platform. No prescription required for personal use.

biotricity.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Bioflux
Description

Single-unit cardiac outpatient monitoring (COM) device for physicians

biotricity.com
+5 more records
Core offering1 text field

Biotricity designs, manufactures, and sells FDA-cleared remote cardiac monitoring hardware — including Bioflux, Biocore, Biocore Pro, Bioheart, and Biokit — that capture continuous ECG and vital-sign data via built-in cellular and Bluetooth connectivity and feed it to physicians through the proprietary Biocare cloud platform. Its offerings support arrhythmia detection, Holter monitoring, remote patient monitoring, chronic cardiac disease management, and direct-to-consumer at-home heart analysis (HeartSecure) for both clinical and personal use.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 3-5 day report turnaround vs 2+ weeks industry standard
+3 more records
Product overview1 text field

Biotricity offers a comprehensive suite of remote cardiac monitoring solutions for medical and consumer markets. The portfolio consists of five core hardware products integrated through the Biocare software platform: Bioflux (FDA-cleared cardiac outpatient monitoring device with cellular technology), Biocore and Biocore Pro (3-lead wireless cardiac monitors with Bluetooth/cellular connectivity), Bioheart (personal 24/7 heart rhythm monitoring for individuals), and Biokit (remote patient monitoring kit with vitals measurement tools). These devices integrate with the Biocare disease management platform which provides chronic care management, telemedicine, and bi-directional communication. The company also offers HeartSecure, an at-home cardiac monitoring service. The products are designed to work together to provide a holistic approach to cardiac diagnostics, remote patient monitoring, and chronic disease management.

Product and service7 records
1Bioflux
CategoryRemote cardiac monitoring devices
Description

FDA-cleared cardiac outpatient monitoring (COM) device that captures ECG data wirelessly through cellular technology, continuously analyzes it for anomalies, and automatically transmits data for physician review. Intended for healthcare providers diagnosing cardiac events in outpatient settings.

2Biocore
CategoryRemote cardiac monitoring devices
Description

3-lead wireless cardiac monitor in a compact patch form with Bluetooth connectivity, supporting up to 30 days of recording with automated data offloading and results delivered in 3-5 days (compared to 2 weeks for traditional Holter monitors). FDA-cleared, prescription-only device for cardiologists and clinics conducting arrhythmia and Holter monitoring.

3Biocore Pro
CategoryRemote cardiac monitoring devices
Description

World's only 3-channel cardiac monitor with built-in SIM card for cellular connectivity, enabling automated data transfer without manual downloads via Bluetooth and cellular. Designed for clinics needing real-time data transfer and remote ECG access for rapid diagnosis of heart conditions.

4Bioheart
CategoryConsumer cardiac wearables
Description

Personal heart rhythm monitoring device providing truly continuous 24/7 recording with 3 heart views (3 true or 12 derived), designed for lifestyle management and personal heart health tracking without requiring a prescription. Sold through shop.bioheart.com for individual consumers.

5Biokit
CategoryRemote patient monitoring kits
Description

FDA-cleared remote patient monitoring kit including pulse oximeter, blood pressure cuff, and digital thermometer for measuring temperature, blood pressure, and blood oxygen levels. Compatible with iOS and Android devices, designed for chronic disease management and telehealth integration.

6Biocare
CategoryCardiac care management software platform
Description

Holistic heart disease management platform combining chronic care management, remote patient monitoring, cardiac diagnostics, lifestyle management, bi-directional communication, and telemedicine into a single cloud-based portal that gives physicians a 360-degree view of patient heart health.

7HeartSecure
CategoryDirect-to-consumer cardiac monitoring services
Description

At-home cardiac monitoring service providing a 10-day comprehensive heart analysis for $149-$199, including device, prepaid return shipping, expert cardiologist review, and detailed heart health report delivered within 72 hours. Available directly to individuals without a prescription.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Emerging player combining digital stethoscopes with AI-powered ECG analysis (CORE 500) for clinicians. Comparable in bringing consumer-grade form factors and AI diagnostics into the cardiac monitoring workflow that Biotricity targets with Biocore/Biocare.

TypeDirect peer
Description

Competes with Biotricity's Bioheart in consumer/DTC ECG monitoring (KardiaMobile and KardiaMobile 6L). Overlapping target customers (health-conscious individuals, AFib patients) with both prescription and non-prescription channels, and similar dual B2B/B2C go-to-market.

TypeDirect peer
Description

Direct competitor in ambulatory cardiac monitoring with the Zio long-term continuous ECG patch service. iRhythm competes head-to-head with Biotricity's Biocore/Biocore Pro for cardiology clinic and electrophysiologist prescriptions using a similar reimbursement-driven GTM.

TypeEmerging player
Description

Early-stage cardiac diagnostics company developing a credit-card-sized 3D ECG device for synthesized 12-lead readings. Comparable as a small-cap remote cardiac monitoring innovator targeting the same cardiology and at-home patient segments as Biotricity.

TypeBroad incumbent
Description

Large incumbent in cardiac diagnostics, implantable loop recorders (LINQ), and remote monitoring (CareLink). Overlaps with Biotricity in cardiology diagnostics and remote patient monitoring but operates a much broader cardiovascular device portfolio at scale.

TypeDirect peer
Description

Was a direct competitor in mobile cardiac telemetry and Holter monitoring (BodyGuardian) before being acquired by Boston Scientific. Highly comparable product portfolio, customer base (cardiologists), and remote cardiac monitoring business model.

TypeBroad incumbent
Description

Incumbent in hospital patient monitoring and ECG diagnostics with MUSE cardiology information systems. Comparable as a cardiac monitoring infrastructure vendor competing for the same clinician and health-system budgets as Biotricity, but with a much broader diagnostic imaging portfolio.

TypeBroad incumbent
Description

Broad incumbent offering legacy Holter, event monitoring, and centralized cardiac telemetry services through its Patient Monitoring business. Competes with Biotricity for hospital and cardiology clinic remote cardiac monitoring spend as part of a much wider medtech portfolio.

TypeBroad incumbent
Description

Incumbent in vital signs monitoring (BP, SpO2, temperature) comparable to Biotricity's Biokit, with broader ambulatory and bedside patient monitoring offerings distributed into physician offices and hospitals globally.

10Abbott
TypeBroad incumbent
Description

Incumbent with insertable cardiac monitors (Confirm Rx, Jot Dx) and a Connected Health remote monitoring platform. Directly overlaps Biotricity's cardiac monitoring franchise with implantable and external devices sold to electrophysiologists.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biotricity

Remote cardiac monitoring devicesbiotricity.com

Biotricity is a Nasdaq-listed medical technology company that develops FDA-cleared remote cardiac monitoring devices — including Bioflux, Biocore Pro, Bioheart, and Biokit — and the Biocare cloud platform for cardiac diagnostics, remote patient monitoring, and chronic care management serving physicians, cardiology clinics, and consumers.

What Biotricity does

Biotricity Inc. (NASDAQ: BTCY) is a medical technology company headquartered in Redwood City, California, that develops FDA-cleared remote cardiac monitoring hardware and an integrated cloud-based disease management platform. Founded in 2014–2015 by Dr. Waqaas Al-Siddiq and listed on Nasdaq in 2021, the company targets two distinct end markets: clinical cardiology (via physician-prescribed devices reimbursable under RPM and Holter CPT codes) and consumer health (via direct-to-consumer e-commerce). Its core product portfolio spans Bioflux (cellular cardiac outpatient telemetry), Biocore and Biocore Pro (3-lead wireless cardiac monitors — the latter with a built-in SIM card), Bioheart (personal 24/7 heart rhythm monitoring), Biokit (multi-vital RPM kit with blood pressure cuff, pulse oximeter, and thermometer), and the Biocare software platform that unifies diagnostics, remote patient monitoring, telemedicine, and chronic care management.

The Biocare platform functions as the technical backbone across the portfolio: continuous ECG streams from Biotricity devices are analyzed using AI-driven anomaly detection, transmitted automatically via cellular or Bluetooth, and surfaced to physicians through a diagnostic portal with automated reporting and threshold-based alerts. The Biocore Pro is described as the only 3-channel cardiac monitor with integrated cellular data transfer, and devices such as Biocore support up to 30 days of recording with daily recharging. Hardware is supported by 15 issued patents and 14 pending applications covering 3-lead ECG architectures, cellular connectivity, and a versatile multi-sensor patch/watch form factor.

Biotricity generates revenue from four streams: hardware/device sales (Bioflux, Biocore, Biocore Pro, Bioheart, Biokit), recurring subscription revenue from the Biocare platform, insurance-reimbursable RPM services billed by clinics, and one-time consumer service fees (notably the HeartSecure 10-day program at $149–$199). The company distributes through physician/clinic direct sales (over 2,500 healthcare professionals using Biocore), the Biodirect direct-to-patient shipping program, healthcare provider networks, and its own e-commerce storefronts. As of Q3 FY2026, quarterly revenue was $3.99 million, with 9-month FY2025 revenue of $11.7 million (up 16% year-over-year); however, the company carries an accumulated deficit of $142.1 million and a working capital deficiency of $18.8 million, signaling that growth has not yet translated to profitability.

Biotricity firmographics

Firmographics
Name
Biotricity
Legal name
Biotricity Inc.
Website
https://biotricity.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Biotricity is a Nasdaq-listed medical technology company that develops FDA-cleared remote cardiac monitoring devices — including Bioflux, Biocore Pro, Bioheart, and Biokit — and the Biocare cloud platform for cardiac diagnostics, remote patient monitoring, and chronic care management serving physicians, cardiology clinics, and consumers.
Ownership category
akta.pro rank

Biotricity industry classification

Industry
Product category
Remote cardiac monitoring devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYCRACAQAC
ECG/EKG & Heart Rhythm Monitors (Consumer)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)

Keywords

  • Remote cardiac monitoring
  • Medical monitoring devices
  • Heart rhythm monitoring
  • Remote patient monitoring
  • Cardiac diagnostics platform

Where Biotricity is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Biotricity business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. Device/Hardware Sales: Sale of FDA-cleared cardiac monitoring devices including Biocore, Biocore Pro, Bioheart, and Biokit to healthcare providers and consumers.
  2. Subscription/Recurring Revenue: Recurring revenue from subscription services including cloud data storage, diagnostic analysis, and platform access fees for healthcare providers using Biocare.
  3. Insurance Reimbursement: Healthcare providers can bill insurance for remote patient monitoring services using Biotricity devices. Biocore Pro enables physician-enabled billing where clinic revenue from claims is paid directly to the clinic, not the device vendor.
  4. HeartSecure Program: One-time cardiac monitoring service at $149-$199 for 10-day comprehensive heart analysis including device rental, cardiologist review, and detailed report delivery.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goHeartSecure - 10-Day At-Home Cardiac Monitoring
OtherMulti-year contractBiocore/Biocore Pro - Physician Prescribed
SubscriptionMonthlyBioheart - Consumer Direct

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Biotricity product offering

Product offering

Core offering

Biotricity designs, manufactures, and sells FDA-cleared remote cardiac monitoring hardware — including Bioflux, Biocore, Biocore Pro, Bioheart, and Biokit — that capture continuous ECG and vital-sign data via built-in cellular and Bluetooth connectivity and feed it to physicians through the proprietary Biocare cloud platform. Its offerings support arrhythmia detection, Holter monitoring, remote patient monitoring, chronic cardiac disease management, and direct-to-consumer at-home heart analysis (HeartSecure) for both clinical and personal use.

Product overview

Biotricity offers a comprehensive suite of remote cardiac monitoring solutions for medical and consumer markets. The portfolio consists of five core hardware products integrated through the Biocare software platform: Bioflux (FDA-cleared cardiac outpatient monitoring device with cellular technology), Biocore and Biocore Pro (3-lead wireless cardiac monitors with Bluetooth/cellular connectivity), Bioheart (personal 24/7 heart rhythm monitoring for individuals), and Biokit (remote patient monitoring kit with vitals measurement tools). These devices integrate with the Biocare disease management platform which provides chronic care management, telemedicine, and bi-directional communication. The company also offers HeartSecure, an at-home cardiac monitoring service. The products are designed to work together to provide a holistic approach to cardiac diagnostics, remote patient monitoring, and chronic disease management.

Differentiator

Problem solved

Functional benefit

Brands

  • Bioflux: Single-unit cardiac outpatient monitoring (COM) device for physicians
  • Biocore Pro
  • Bioheart
  • Biokit
  • Biocare
  • HeartSecure

Products and services

  • Bioflux FDA-cleared cardiac outpatient monitoring (COM) device that captures ECG data wirelessly through cellular technology, continuously analyzes it for anomalies, and automatically transmits data for physician review. Intended for healthcare providers diagnosing cardiac events in outpatient settings.
  • Biocore 3-lead wireless cardiac monitor in a compact patch form with Bluetooth connectivity, supporting up to 30 days of recording with automated data offloading and results delivered in 3-5 days (compared to 2 weeks for traditional Holter monitors). FDA-cleared, prescription-only device for cardiologists and clinics conducting arrhythmia and Holter monitoring.
  • Biocore Pro World's only 3-channel cardiac monitor with built-in SIM card for cellular connectivity, enabling automated data transfer without manual downloads via Bluetooth and cellular. Designed for clinics needing real-time data transfer and remote ECG access for rapid diagnosis of heart conditions.
  • Bioheart Personal heart rhythm monitoring device providing truly continuous 24/7 recording with 3 heart views (3 true or 12 derived), designed for lifestyle management and personal heart health tracking without requiring a prescription. Sold through shop.bioheart.com for individual consumers.
  • Biokit FDA-cleared remote patient monitoring kit including pulse oximeter, blood pressure cuff, and digital thermometer for measuring temperature, blood pressure, and blood oxygen levels. Compatible with iOS and Android devices, designed for chronic disease management and telehealth integration.
  • Biocare Holistic heart disease management platform combining chronic care management, remote patient monitoring, cardiac diagnostics, lifestyle management, bi-directional communication, and telemedicine into a single cloud-based portal that gives physicians a 360-degree view of patient heart health.
  • HeartSecure At-home cardiac monitoring service providing a 10-day comprehensive heart analysis for $149-$199, including device, prepaid return shipping, expert cardiologist review, and detailed heart health report delivered within 72 hours. Available directly to individuals without a prescription.

Quantifiable outcome

  • 3-5 day report turnaround vs 2+ weeks industry standard
  • +3 more outcomes

Companies that use Biotricity

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Biotricity technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Biotricity partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Biotricity competitors and assessment

Company assessment

Emerging players

  • Eko Health: Emerging player combining digital stethoscopes with AI-powered ECG analysis (CORE 500) for clinicians. Comparable in bringing consumer-grade form factors and AI diagnostics into the cardiac monitoring workflow that Biotricity targets with Biocore/Biocare.
  • HeartBeam: Early-stage cardiac diagnostics company developing a credit-card-sized 3D ECG device for synthesized 12-lead readings. Comparable as a small-cap remote cardiac monitoring innovator targeting the same cardiology and at-home patient segments as Biotricity.

Direct peers

  • AliveCor: Competes with Biotricity's Bioheart in consumer/DTC ECG monitoring (KardiaMobile and KardiaMobile 6L). Overlapping target customers (health-conscious individuals, AFib patients) with both prescription and non-prescription channels, and similar dual B2B/B2C go-to-market.
  • iRhythm Technologies: Direct competitor in ambulatory cardiac monitoring with the Zio long-term continuous ECG patch service. iRhythm competes head-to-head with Biotricity's Biocore/Biocore Pro for cardiology clinic and electrophysiologist prescriptions using a similar reimbursement-driven GTM.
  • Preventice Solutions (Boston Scientific): Was a direct competitor in mobile cardiac telemetry and Holter monitoring (BodyGuardian) before being acquired by Boston Scientific. Highly comparable product portfolio, customer base (cardiologists), and remote cardiac monitoring business model.

Broad incumbents

  • Medtronic: Large incumbent in cardiac diagnostics, implantable loop recorders (LINQ), and remote monitoring (CareLink). Overlaps with Biotricity in cardiology diagnostics and remote patient monitoring but operates a much broader cardiovascular device portfolio at scale.
  • GE HealthCare: Incumbent in hospital patient monitoring and ECG diagnostics with MUSE cardiology information systems. Comparable as a cardiac monitoring infrastructure vendor competing for the same clinician and health-system budgets as Biotricity, but with a much broader diagnostic imaging portfolio.
  • Philips (Cardiac Monitoring): Broad incumbent offering legacy Holter, event monitoring, and centralized cardiac telemetry services through its Patient Monitoring business. Competes with Biotricity for hospital and cardiology clinic remote cardiac monitoring spend as part of a much wider medtech portfolio.
  • Welch Allyn / Baxter (Hillrom): Incumbent in vital signs monitoring (BP, SpO2, temperature) comparable to Biotricity's Biokit, with broader ambulatory and bedside patient monitoring offerings distributed into physician offices and hospitals globally.
  • Abbott: Incumbent with insertable cardiac monitors (Confirm Rx, Jot Dx) and a Connected Health remote monitoring platform. Directly overlaps Biotricity's cardiac monitoring franchise with implantable and external devices sold to electrophysiologists.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Biotricity social profiles

Digital presence

Biotricity compliance and trust

Trust signal

Compliance2 records

Biotricity financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biotricity leadership team

Management profile

Number of profiles

Profiles9 records

Biotricity funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biotricity M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biotricity

What does Biotricity do?

Biotricity designs, manufactures, and sells FDA-cleared remote cardiac monitoring hardware — including Bioflux, Biocore, Biocore Pro, Bioheart, and Biokit — that capture continuous ECG and vital-sign data via built-in cellular and Bluetooth connectivity and feed it to physicians through the proprietary Biocare cloud platform. Its offerings support arrhythmia detection, Holter monitoring, remote patient monitoring, chronic cardiac disease management, and direct-to-consumer at-home heart analysis (HeartSecure) for both clinical and personal use.

Is Biotricity a public or private company?

Biotricity is a public company. It is classified as public and is currently operating.

When was Biotricity founded?

Biotricity was founded in 2015. It employs 51 to 100 people.

Where is Biotricity based?

Biotricity is headquartered in Redwood City, United States, in the North America region.

How does Biotricity make money?

Four revenue lines are on record. Device/Hardware Sales are the primary driver. The others are subscription/Recurring Revenue, insurance Reimbursement and heartSecure Program.

Who are Biotricity's main competitors?

Emerging players on record are Eko Health and HeartBeam. Direct peers are AliveCor, iRhythm Technologies and Preventice Solutions (Boston Scientific). Broad incumbents are Medtronic, GE HealthCare, Philips (Cardiac Monitoring), Welch Allyn / Baxter (Hillrom) and Abbott.

Does Biotricity have an API?

No public API is recorded for Biotricity.

What industry is Biotricity in?

Biotricity's product category is Remote cardiac monitoring devices. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PRLogBiotricity Advances Connected Cardiac Care Through Innovative Monitoring TechnologiesBiotricity develops connected cardiac monitoring technologies, including mobile cardiac monitors and extended Holter monitoring, to support long-term patient assessment. The company aims to improve healthcare accessibility and strengthen long-term patient outcomes through wearable devices and digital platforms.AInvestThe 10-K That Won't FileBiotricity filed a Notice of Late Filing (NT 10-K) with the SEC, missing its annual report deadline for the second consecutive year despite reporting Q3 fiscal 2026 revenue of $4 million, up 10.2% year-over-year with an 81.9% gross margin. The filing delay, following an already-late 10-K for fiscal 2025, raised concerns about potential audit disputes or doubts over the company's ability to continue operations, triggering a 16% stock drop to approximately 29 cents. The article highlights the disconnect between management's positive earnings narrative and the concerning signal sent by the company's inability to deliver verified annual financials, with the stock now trading on OTCQB.NewsfileBiotricity, Inc to Present at the LD Micro Invitational XVIBiotricity, Inc will present at the 16th Annual LD Micro Invitational in Los Angeles on May 18, 2026, at 12:30 PM PDT. Dr. Waqaas Al-Siddiq, founder and CEO, will speak on behalf of the company. The event runs May 18-19 and features micro and small-cap companies.Defense WorldBiotricity (NASDAQ:BTCY) Trading Down 1.7% – Should You Sell?Biotricity, Inc. (NASDAQ:BTCY) stock declined 1.7% on Tuesday, trading at $0.2260 per share with approximately 19,763 shares exchanged during mid-day trading, well below the average daily volume of 49,861 shares. The company reported quarterly earnings of ($0.04) per share, beating analysts' consensus estimates of ($0.08) by $0.04, with revenue of $3.99 million for the quarter.Defense WorldContrasting PetVivo (NASDAQ:PETV) & Biotricity (NASDAQ:BTCY)The article compares the financial and risk profiles of Biotricity and PetVivo, highlighting differences in profitability, volatility, and valuation. PetVivo has lower revenue but higher earnings and a lower price-to-earnings ratio than Biotricity.BenzingaBiotricity Q3 2026 Earnings Call: Complete Transcript - BIOTRICITY INC by Biotricity Inc. (OTC:BTCY)Biotricity reported a 10.2% increase in revenue to $4 million for the third quarter of fiscal 2026 ended December 31, 2025, driven by its subscription-based cardiac monitoring technology model and FDA-cleared devices including BioCor Pro and BioCare. The company achieved positive EBITDA of $280,000 for the third consecutive quarter, with gross profit improving 17.6% to $3.3 million and gross margin expanding to 81.5%, while net loss narrowed to $1.1 million from $1.3 million year-over-year. Management indicated expectations to shift to net income positive in fiscal 2026, supported by growing adoption of its digital health ecosystem which has expanded to 44,000 app users and over 2,500 provider relationships.Seeking AlphaBiotricity, Inc. (BTCY) Q3 2026 Earnings Call TranscriptBiotricity held a conference call to discuss its Q3 2026 financial results, which ended on December 31, 2025, and shared operational highlights. The company also provided a forward-looking statement as part of the update.GlobeNewswireBiotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDABiotricity Inc. reported its Q3 fiscal 2026 results ending December 31, 2025, with revenue growing 10.2% year-over-year to $4 million, driven by increasing adoption of its remote cardiac monitoring solutions. The company achieved its third consecutive quarter of positive EBITDA, improved gross margins to 81.5%, and reduced net loss by 13% to $1.1 million, while maintaining 90%+ customer retention. The company is advancing strategic regulatory approvals in Canada, Saudi Arabia, and Argentina and expects FDA clearance for its AI clinical model in the coming months.BenzingaEarnings Preview: Biotricity - BIOTRICITY INC by Biotricity Inc. (OTC:BTCY)Biotricity Inc. (OTC:BTCY) is scheduled to release its quarterly earnings report on February 11, 2026, with analysts estimating a loss of $0.08 per share. The company's shares have declined 21.69% over the past 52 weeks, trading at $0.4631 as of February 9, with recent quarters also showing negative earnings performance. Given the consistent downward trend in both stock price and earnings, long-term shareholders are described as likely bearish heading into the upcoming announcement.TradingView3 Healthcare IT Stocks Up More Than 20% in 2025 With More Room to RunIn 2025, three US-listed healthcare IT stocks — Hims & Hers Health, Inc., Biotricity, Inc., and Privia Health Group, Inc. — have each gained over 20% in share price, driven by demand in telehealth, biometric monitoring, and physician-enablement technology.